Our study found that proxalutamide can synergistically block the SREBP-1/FASN/lipogenesis and AR signal axis of PCa cells, which provides new insight into the underlying molecular basis of the superior therapeutic activity of proxalutamide in PCa. This evidence concerns the gene SREBF1 and posterior cortical atrophy.